Last reviewed · How we verify
Gardasil as three dose regimen
Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18.
Gardasil is a recombinant quadrivalent human papillomavirus (HPV) vaccine that stimulates the immune system to produce antibodies against HPV types 6, 11, 16, and 18. Used for Prevention of cervical cancer caused by HPV types 16 and 18, Prevention of genital warts caused by HPV types 6 and 11, Prevention of anal cancer and other HPV-related malignancies.
At a glance
| Generic name | Gardasil as three dose regimen |
|---|---|
| Sponsor | Serum Institute of India Pvt. Ltd. |
| Drug class | Recombinant quadrivalent HPV vaccine |
| Target | Human papillomavirus (HPV) types 6, 11, 16, 18 L1 capsid protein |
| Modality | Biologic |
| Therapeutic area | Oncology / Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains virus-like particles (VLPs) derived from the major capsid protein (L1) of four HPV types. When administered, these VLPs trigger a humoral immune response that generates neutralizing antibodies against HPV, preventing infection and subsequent development of HPV-related diseases. The three-dose regimen is designed to achieve optimal immunogenicity and long-term protection.
Approved indications
- Prevention of cervical cancer caused by HPV types 16 and 18
- Prevention of genital warts caused by HPV types 6 and 11
- Prevention of anal cancer and other HPV-related malignancies
Common side effects
- Injection site pain, swelling, or erythema
- Headache
- Myalgia
- Fever
- Nausea
Key clinical trials
- HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini (PHASE4)
- Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gardasil as three dose regimen CI brief — competitive landscape report
- Gardasil as three dose regimen updates RSS · CI watch RSS
- Serum Institute of India Pvt. Ltd. portfolio CI